1. P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410 randomized phase II trial. (19th September 2018) Authors: French, P J; Kros, J; de Heer, I; Ansell, P; Looman, J; Bain, E; Morfouace, M; Gorlia, T; Golfinopoulos, V; van den Bent, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P11.08 Defining EGFR amplification status for clinical trial inclusion. (6th September 2019) Authors: French, P; Eoli, M; Sepulveda, J; de Heer, I; Kros, J M; Walenkamp, A; Frenel, J; Franceschi, E; Clement, P; Weller, M; Ansell, P; Looman, J; Bain, E; Morfouace, M; Gorlia, T; van den Bent, M Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗